Bourut C, Chenu E, Godenèche D, Madelmont J C, Maral R, Mathé G, Meyniel G
Br J Pharmacol. 1986 Nov;89(3):539-46. doi: 10.1111/j.1476-5381.1986.tb11154.x.
2-Chloroethyl nitrosocarbamoylcystamine or ICIG-1325 (CNCC) is a lipid-soluble isomeric mixture of nitrosoureas. Its dose-effect relationship on L1210 leukaemia is characterized by a large maximally efficient dose-range (MEDR), greater than that of other nitrosoureas. CNCC also demonstrated significant therapeutic activity on intracerebrally (i.c.) transplanted L1210 leukaemia and on six transplanted solid tumours, TM2 mammary carcinoma, M555 ovarian carcinoma, B16 melanoma, glioma 26, 3LL, Lewis lung carcinoma and colon 26 carcinoma. It was inactive on fibrosarcoma ICIG-Ci4. Its antitumour activity spectrum is wider than that of the related compounds 2-[3-(2-chloroethyl) 3-nitrosoureido]D-glucopyranose (CZT), (chloro-2-ethyl)-1(ribofuranosyl-isopropylidene-2'-3' paranitrobenzoate-5')-3 nitrosourea (RFCNU), and (chloro-2-ethyl)-1 (ribopyranosyl triacetate-2'-3'-4')-3 nitrosourea (RPCNU). A study of its metabolic disposition in animals has shown that CNCC undergoes extensive first-pass metabolism leading to the formation of four main plasma metabolites. These metabolites are water-soluble nitrosoureas that arose from the bioreduction of the disulphide bridge followed by the methylation and the oxidation of the thiol groups. Experimental screening was performed with these chemically synthesized metabolites. Both N'-(2-chloroethyl)-N-[2-(methylsulphinyl)ethyl]-N'-nitrosourea (CMSOEN2) and N'-(2-chloroethyl)-N-[2-(methylsulphonyl)ethyl]-N'-nitrosourea (CMSO2EN2) are very active on L1210 leukaemia grafted intraperitoneally (i.p.) and i.c., L40 leukaemia, B16 melanoma, glioma 26 and Lewis lung carcinoma. Their effectiveness is better than that of the parent compound CNCC. In addition,the percentage of mice cured after CMSOEN2 or CMSO2EN2 treatment is increased especially on B16 melanoma and glioma 26. 6 Haematological toxicity of both active metabolites is lower than that of CNCC, particularly on platelets which is the main toxicity location due to nitrosoureas.
2-氯乙基亚硝基氨基甲酰胱胺或ICIG-1325(CNCC)是一种脂溶性亚硝基脲的异构体混合物。其对L1210白血病的剂量效应关系的特点是最大有效剂量范围(MEDR)很大,大于其他亚硝基脲。CNCC对脑内(i.c.)移植的L1210白血病以及六种移植实体瘤,即TM2乳腺癌、M555卵巢癌、B16黑色素瘤、胶质瘤26、3LL、Lewis肺癌和结肠癌26也显示出显著的治疗活性。它对纤维肉瘤ICIG-Ci4无活性。其抗肿瘤活性谱比相关化合物2-[3-(2-氯乙基)3-亚硝基脲基]D-吡喃葡萄糖(CZT)、(2-氯乙基)-1(呋喃核糖基-异亚丙基-2'-3'-对硝基苯甲酸酯-5')-3亚硝基脲(RFCNU)和(2-氯乙基)-1(三乙酸吡喃核糖基-2'-3'-4')-3亚硝基脲(RPCNU)更宽。对其在动物体内代谢情况的研究表明,CNCC经历广泛的首过代谢,导致形成四种主要的血浆代谢物。这些代谢物是水溶性亚硝基脲,它们由二硫键的生物还原产生,随后是硫醇基团的甲基化和氧化。对这些化学合成的代谢物进行了实验筛选。N'-(2-氯乙基)-N-[2-(甲基亚磺酰基)乙基]-N'-亚硝基脲(CMSOEN2)和N'-(2-氯乙基)-N-[2-(甲基磺酰基)乙基]-N'-亚硝基脲(CMSO2EN2)对腹腔内(i.p.)和脑内移植的L1210白血病、L40白血病、B16黑色素瘤、胶质瘤26和Lewis肺癌都非常有活性。它们的有效性优于母体化合物CNCC。此外,用CMSOEN2或CMSO2EN2治疗后治愈的小鼠百分比增加,尤其是对B16黑色素瘤和胶质瘤26。两种活性代谢物的血液学毒性低于CNCC,特别是对血小板,血小板是亚硝基脲主要的毒性作用部位。